yajuan su

Dr. yajuan su


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2024 in Journal of Cell Communication and Signaling
Verified
Journal Article
Open access
NLNana Li
Nana Li
PYPeihua Yan
Peihua Yan
LGLing Guo
Ling Guo
HWHuiyan Wang
Huiyan Wang
BCBaohong Cui
Baohong Cui
YSyajuan su
yajuan su
Chemo‐resistance in ovarian cancer is currently a major obstacle to the treatment and recovery of ovarian cancer. Therefore, identifying factors associated with chemo‐resistance in ovarian cancer may reverse chemo‐sensitization. Using isobaric tags for relative and absolute quantitation (ITRAQ) technology, we found a small molecule peptide with annexin 1 (ANXA1) as a precursor protein. Then, we explored the effects and mechanisms of this small molecule peptide on the proliferation, apoptosis, and drug resistance of ovarian cancer resistant cells through CCK‐8, EdU cell proliferation assay, Annexin V‐FITC/PI assay, Western blot,qRT‐PCR. ANXA114‐26 was highly expressed in the serums of sensitive patients. ANXA114‐26 promoted apoptosis of ovarian cancer cells and increased the sensitization of ovarian cancer cells to cisplatin. The ANXA114‐26 and ANXA1 competitively bind formyl peptide receptors (FPR). ANXA114‐26 decreased multidrug resistance‐associated protein 1 (MRP1) expression in ovarian cancer cells through the FPR/Cyclin D1/NF‐ĸBp65 pathway. We found a peptide derived named ANXA114‐26 in the serum of ovarian cancer patients. It can reduce ovarian cancer cell proliferation and reduce MRP1 expression through the FPR/Cyclin D1/NF‐ĸBp65 pathway.

8 November 2025 in Medical Oncology
Verified
Journal Article
Open access
PDF file
LGLing Guo
Ling Guo
HWHaibing Wang
Haibing Wang
NLNana Li
Nana Li
JWJing Wang
Jing Wang
MYMing Yu
Ming Yu
LTLichen Teng
Lichen Teng
Ovarian cancer is a gynecologic malignancy with high mortality and poor prognosis. Chemoresistance is a key cause of ovarian cancer recurrence and metastasis. It has been found that some bioactive peptides can inhibit the growth and metastasis of cancer cells and promote cell apoptosis, thus exerting anti-cancer effects. Tβ4–17 is a small polypeptide that we selected using ITRAQ technology, and its precursor protein is thymosin β4. This study mainly investigated its effect in combination with cisplatin (DDP) on the proliferation, migration and apoptosis of ovarian cancer resistant cells and related molecular mechanisms. Our results showed that Tβ4–17 peptide combined with DDP significantly inhibited the proliferation and migration of drug resistance cells in ovarian cancer, promoted apoptosis, and increased the chemo-sensitivity of ovarian cancer cells to DDP. In addition, qRT-PCR and Western blot showed that NF-κB was significantly highly expressed in DDP-resistant cells of ovarian cancer. After application of NF-κB inhibitors and activators, Western blot, CCK8, EDU fluorescence proliferation assay, and cell scratch assay showed that Tβ4–17 peptide down-regulated NF-κB p65 protein expression and inhibited cell proliferation and migration. In conclusion, our study demonstrates that Tβ4–17 peptide enhances the sensitivity of ovarian cancer cells to DDP by down-regulating NF-κB expression.

22 September 2026 in Cancer Gene Therapy
Verified
Journal Article
Closed access
PDF file
ALAn-Rui Li
An-Rui Li
JXJing-Wen Xu
Jing-Wen Xu
ZWZhi-Hang Wu
Zhi-Hang Wu
ZKZhi-Jian Kang
Zhi-Jian Kang
RLRun-Sheng Luo
Run-Sheng Luo
LTLi-Chen Teng
Li-Chen Teng